Evidence map›Paper›PMID 40608141›Full record

ArticleRheumatology international2025

Validity and reliability of the Flare-OA scale for hip and knee osteoarthritis in a Turkish population: item reduction with Rasch analysis.

Mehmet Tuncay Duruöz, Halise Hande Gezer, Jonathan Epstein, Marc Soudant, Francis Guillemin

Abstract readValidation Study
In one paragraph

Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mehmet Tuncay DuruözMarmara University School of Medicine, Rheumatology, Istanbul, Türkiye. tuncayduruoz@gmail.com.ORCID 0000-0003-3584-2788
Halise Hande GezerMarmara University School of Medicine, Rheumatology, Istanbul, Türkiye. hande_snc@hotmail.com.ORCID 0000-0001-8790-304X
Jonathan EpsteinCHRU, Inserm, Université de Lorraine, CIC Epidémiologie Clinique, Nancy, France. j.epstein@chru-nancy.fr.ORCID 0000-0001-7908-7636
Marc SoudantUniversité de Lorraine, Inserm, UMR 1319 INSPIIRE, Nancy, France. m.soudant@chru-nancy.fr.ORCID 0000-0001-5814-6924
Francis GuilleminCHRU, Inserm, Université de Lorraine, CIC Epidémiologie Clinique, Nancy, France. francis.guillemin@chru-nancy.fr.ORCID 0000-0002-9860-7024

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe Flare-OA questionnaire is a self-reported instrument developed to assess flare in individuals with knee and/or hip osteoarthritis. This study aimed to translate and culturally adapt both the original and short versions of the Flare-OA into Turkish.

methodsThe Turkish version of the questionnaire was obtained through a process of cross-cultural adaptation and translation. Patients aged 45 years or older with clinically and radiologically confirmed OA of the knee or hip were recruited. The Flare-OA scale, originally consisting of 33 items, was shortened to 19 items and then to a final 16-item version through Rasch analysis. The internal consistency of the Flare-OA was measured using Cronbach's alpha, and its stability over time was tested by evaluating test-retest reliability over a 15-day interval in patients with no clinical changes. The sensitivity to change was determined by calculating the standardized response mean (SRM) in those who reported symptom variation during the follow-up. Convergent validity was assessed by analyzing the correlations between the scale and previously validated measures, including the Hip Disability and Osteoarthritis Outcome Score (HOOS-PS), the Knee Injury and Osteoarthritis Outcome Score (KOOS), and the Mini-Osteoarthritis Knee and Hip Quality of Life Questionnaire (Mini-OAKHQOL).

resultsThe study included 185 participants, of whom 71.9% were women, with a mean age of 63.2 years (SD:9.1). Of these, 160 patients (86.5%) had knee OA and 25 (13.5%) had hip OA. In the past four weeks, 70 patients (37.8%) reported a worsening of symptoms in the affected joint. Cronbach's alpha coefficient was 0.987 (95% CI 0.984-0.990) for the 33-item and 0.972 (95% CI 0.966-0.978) for the 16-item. The intraclass correlation coefficient was 0.913 and 0.912 for the test-retest reliability (n=79) of the 33- and 16-item tests, respectively. Sensitivity to change was good in 9 patients with flare improvement [SRM 1.2 (95% CI 0.6-1.7), SRM 1 (95% CI 0.5-1.5), for 33- and 16-items, respectively] over the period. Discriminant validity was supported by statistically significant score differences between patients with and without flare for both the 33-item [36.2; 95% CI 29.9-42.6; SEM: 8; p<.0001] and the 16-item [36.7; 95% CI 30.3-43.0; SEM: 8.1; p<.0001] versions. There was a significant and negative correlation between the Flare-OA score and KOOS and mini-OAKHQOL (p<0.05). 16-item Rasch modeling allowed us to reduce the questionnaire to a 16-item version with good fit and a satisfactory interval scale.

conclusionThe Turkish versions of the Flare-OA questionnaires (33- and 16-item) showed high reliability, validity, and clinical utility in evaluating flares in knee and hip OA. The 16-item version appears especially useful for routine use, although further validation is needed due to the limited sample size in the hip OA subgroup.

Indexed as

Osteoarthritis, HipOsteoarthritis, KneeAgedDisability EvaluationFemaleHumansMaleMiddle AgedPredictive Value of TestsQuality of LifeReproducibility of ResultsSeverity of Illness IndexSurveys and QuestionnairesSymptom Flare UpTranslatingTurkeyDisease flaresOsteoarthritis, HipOsteoarthritis, KneePsychometricsQuality of lifeSurveys and questionnaires

Identifiers

PMID40608141
PMCPMC12226661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.